Aquestive (AQST) Q3 2026 Earnings Call Transcript
Aquestive (AQST) reported Q3 2026 earnings, highlighting progress on key milestones. The company resubmitted its ANNAFILM application, outlicensed Libervant, and refinanced debt. It expects over $70M in cash by year-end. ANNAFILM's FDA review is ongoing with a decision expected by March 16, 2027. The company is preparing for a potential US launch and expanding into Canada and Europe. AQST also discussed its pipeline and financial discipline.
How this was made

The 30-second read
Why it matters
Guidance updates provide modest new information but lack quantitative earnings surprises, limiting immediate trading impact.
Market read
The call offers incremental updates on cash and FDA timelines, relevant for biotech investors monitoring pipeline risk.
What to watch
Potential competitive pressure from auto‑injector products and payer reimbursement uncertainties.
Background
Aquestive Therapeutics discussed its pipeline progress, cash position, and upcoming regulatory milestones during its Q3 2026 earnings call.
Ticker impact
The earnings call disclosed updated cash guidance above $70M and a target FDA decision date of March 16, 2027 for Annamil.
potential modest upside if FDA approval occurs before the projected date; downside risk if delays persist
Guidance is incremental and does not contain new financial results; impact hinges on regulatory outcome.
Market effects
Reinforces outlook for the allergy epinephrine market and may influence peer biotech valuations.
US biotech sector sees modest attention; no broader regional effect.
Limited to investors tracking FDA pipeline milestones.
Counterpoint
If FDA delays beyond March 2027, the stock could face pressure despite cash guidance.
Key entities
- companyAquestive Therapeutics
Biopharma developing epinephrine delivery products.
- companyEton Pharmaceuticals
Licensee for Libervant diazepam buccal film.


